Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1825–1848 of 6,771 matching trials from the live ClinicalTrials.gov search.

Filters: Bethesda, Maryland Clear all

Conditions: Dental Caries, Dental Plaque, Periodontal Disease
Interventions: Not listed
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1998 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cerebral Palsy, Muscle Hypertonia
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 6 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Leukemia, Lymphoma
Interventions: rituximab, bryostatin 1; Biological · Drug
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Multiple Myeloma
Interventions: Daratumumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 41
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Duarte, California + 38 more

Conditions: Brain and Central Nervous System Tumors
Interventions: O6-benzylguanine, temozolomide; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Metastatic Breast Cancer
Interventions: Sorafenib, Ixabepilone; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 15
States / cities: Fort Myers, Florida • Terre Haute, Indiana • Louisville, Kentucky + 10 more

Conditions: Diabetes Mellitus
Interventions: AC2993 (exenatide), daclizumab (immunosuppressive); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Stroke
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Healthy
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Depressive Disorder, Healthy, Mental Disorders, Mood Disorders
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Female only
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1988 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Interventions: CAT-8015 20 mcg/kg, CAT-8015 30 mcg/kg, CAT-8015 40 mcg/kg, CAT-8015 50 mcg/kg, CAT-8015 60 mcg/kg; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 7
States / cities: Los Angeles, California • Indianapolis, Indiana • Bethesda, Maryland + 4 more

Conditions: Osteoporosis
Interventions: Romosozumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 55 Years to 85 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 9
States / cities: Tucson, Arizona • Walnut Creek, California • Gainesville, Georgia + 6 more

Conditions: Low Grade Astrocytoma, Low Grade Glioma, Metastatic Low Grade Astrocytoma, Metastatic Low Grade Glioma, WHO Grade 1 Glioma, WHO Grade 2 Glioma
Interventions: Biospecimen Collection, Carboplatin, Echocardiography Test, Magnetic Resonance Imaging, Questionnaire Administration, Selumetinib Sulfate, Vincristine Sulfate; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years to 21 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 124
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 101 more

Conditions: Hepatitis B
Interventions: Entecavir and peginterferon; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 20
States / cities: Los Angeles, California • San Francisco, California • Honolulu, Hawaii + 11 more

Conditions: Gonadal Dysgenesis, Turner's Syndrome
Interventions: Growth Hormone (Humatrope); Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: Female only
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1987 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Coronary Artery Disease
Interventions: Gadobutrol (Gadavist, Gadovist, BAY86-4875); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 15
States / cities: Tucson, Arizona • Los Angeles, California • Atlanta, Georgia + 11 more

Conditions: Cognition Disorders
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)
Interventions: Benralizumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 6 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 8
States / cities: Aurora, Colorado • Bethesda, Maryland • Ann Arbor, Michigan + 5 more

Conditions: Myelodysplastic Syndromes
Interventions: pacritinib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years to 120 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Mild Tricuspid Regurgitation, Moderate Tricuspid Regurgitation, Tricuspid Regurgitation
Interventions: TV Annuloplasty, MVS; Procedure
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 401 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 24
States / cities: Los Angeles, California • Stanford, California • New Haven, Connecticut + 20 more

Conditions: Systemic Lupus Erythematosus
Interventions: Anifrolumab, Placebo; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 22
States / cities: Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 18 more

Conditions: Inflammation In Skeletal Muscle
Interventions: Not listed
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 2 Years to 120 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2032
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Tropical Spastic Paraparesis
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Osteomalacia, Neoplasms
Interventions: Not listed
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: 8 Years to 100 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Study of the Composition of Dental Plaque

Hypertonia in Patients With Cerebral Palsy

Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma

O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy

Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer

Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes

Brain Electrical Stimulation to Enhance Recovery After Stroke

Pharmacokinetic Interactions With Prednisolone in Healthy Volunteers and HIV-infected Patients Receiving Single-Dose Prednisone

The Effect of GnRH on Pitutitary Hormones in Menstrual-Cycle Mood Related Disorders

Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL)

Transition From Alendronate to Romosozumab (AMG 785)

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B

Effect of Biosynthetic Growth Hormone and/or Ethinyl Estradiol on Adult Height in Patients With Turner Syndrome

Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)

PET Scan to Map the Areas of the Brain Involved in Planning

Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment

Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

Evaluating the Benefit of Concurrent Tricuspid Valve Repair During Mitral Surgery

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

Natural History of Inflammatory Muscle Diseases

MRI Brain Studies in Patients With HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis

Catheterization to Locate Mesenchymal Tumors in Patients With Tumor-Induced Osteomalacia or Oncogenic Osteomalacia